5/9/2025

Janusmed sex and gender

Janusmed sex and gender – Dolutegravir

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Dolutegravir

Dolutegravir

Class : C

Show all info

Print

Contact us

  1. Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80:502-14.

  2. Tivicay (dolutegravir). EPAR - Product information. European Medicines Agency (EMA); 2017.

  3. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-43.

  4. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700-8.

  5. Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56-63.

  6. Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31:1853-1858.

  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]

  8. Hivinfektion 2016. Folkhälsomyndigheten (The Public Health Agency of Sweden): Stockholm, Sweden.

  1. Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80:502-14.
  2. Tivicay (dolutegravir). EPAR - Product information. European Medicines Agency (EMA); 2017.
  3. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-43.
  4. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700-8.
  5. Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56-63.
  6. Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31:1853-1858.
  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]
  8. Hivinfektion 2016. Folkhälsomyndigheten (The Public Health Agency of Sweden): Stockholm, Sweden.